Revolution Medicines secures $2 billion funding from Royalty Pharma for global development strategy

From Nasdaq: 2025-06-24 07:33:00

Revolution Medicines, Inc. has partnered with Royalty Pharma for $2 billion in funding to support its global development and commercialization strategy for RAS(ON) inhibitors. The company retains full control over product development and commercialization in the US and internationally, aiming to set new global standards of care. The funding includes $1.25 billion in synthetic royalty monetization on sales of daraxonrasib and $750 million in corporate debt, with flexibility for Revolution Medicines to access $1.25 billion based on specific milestones. This partnership will help the company leverage its assets and create value for shareholders.



Read more at Nasdaq: Revolution Medicines Partners Royalty Pharma On $2 Bln Flexible Funding